Hao Ede - Innovent Biologics CFO Director

All Insiders . USA . 
Stock . Innovent Biologics . Stakeholders . Insider . Hao Ede
IVBXF Stock  USD 4.00  0.53  11.70%   

Insider

Hao Ede is CFO Director of Innovent Biologics
Age 64
Phone86 512 6956 6088
Webhttps://www.innoventbio.com

Innovent Biologics Management Efficiency

The company has return on total asset (ROA) of (0.1372) % which means that it has lost $0.1372 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.287) %, meaning that it generated substantial loss on money invested by shareholders. Innovent Biologics' management efficiency ratios could be used to measure how well Innovent Biologics manages its routine affairs as well as how well it operates its assets and liabilities.
Innovent Biologics has accumulated 2.02 B in total debt with debt to equity ratio (D/E) of 0.29, which may suggest the company is not taking enough advantage from borrowing. Innovent Biologics has a current ratio of 3.15, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Innovent Biologics until it has trouble settling it off, either with new capital or with free cash flow. So, Innovent Biologics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Innovent Biologics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Innovent to invest in growth at high rates of return. When we think about Innovent Biologics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

MD MBAMAIA Biotechnology
55
Christian DavisTelix Pharmaceuticals Limited
N/A
Lena MoranAdamsTelix Pharmaceuticals Limited
N/A
Steve AndreCullinan Oncology LLC
N/A
Andy PorterRelay Therapeutics
N/A
Robert IIArcus Biosciences
52
Alexander BakkerMerus BV
58
Clive BrownOxford Nanopore Technologies
N/A
Sara LeOxford Nanopore Technologies
N/A
BCh BMKronos Bio
40
Sergei GryaznovMAIA Biotechnology
65
Jason BarkerArcus Biosciences
49
Hennie HoogenboomMerus BV
N/A
Harry ShumanMerus BV
N/A
Gordon SangheraOxford Nanopore Technologies
N/A
Joseph McGuireMAIA Biotechnology
66
Carla PoulsonMersana Therapeutics
N/A
Ye MSGenscript Biotech
55
Jacquelyn JDCullinan Oncology LLC
47
Kerry WhalenCullinan Oncology LLC
N/A
Jeff KnightCrinetics Pharmaceuticals
54
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the Peoples Republic of China. Innovent Biologics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 5538 people. Innovent Biologics [IVBXF] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC).

Management Performance

Return On Equity-0.29
Return On Asset-0.14

Innovent Biologics Leadership Team

Elected by the shareholders, the Innovent Biologics' board of directors comprises two types of representatives: Innovent Biologics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Innovent. The board's role is to monitor Innovent Biologics' management team and ensure that shareholders' interests are well served. Innovent Biologics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Innovent Biologics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Min Liu, Chief Officer
Blake Salisbury, Sr Devel
Eduard MD, Pres USA
Yong MD, President
Vivian Zhang, Chief Officer
Dongming Wang, VP Quality
Changshou Gao, VP CTO
Yanju Wang, Joint Sec
Hao Ede, CFO Director
DeChao Yu, Chairman CoFounder

Innovent Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Innovent Biologics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.29
Return On Asset-0.14
Profit Margin(0.68) %
Operating Margin(0.78) %
Current Valuation5.13 B
Shares Outstanding1.53 B
Shares Owned By Insiders7.15 %
Shares Owned By Institutions44.34 %
Price To Book4.22 X
Price To Sales1.39 X

Currently Active Assets on Macroaxis

FFord Motor
GMGeneral Motors
SSentinelOne
GOOGAlphabet Inc Class C
WDWalker Dunlop

Other Information on Investing in Innovent Pink Sheet

Innovent Biologics financial ratios help investors to determine whether Innovent Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Innovent with respect to the benefits of owning Innovent Biologics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY